Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates
The paper presents a classification of adverse drug reactions and their characteristics. Bisphophonates (BP) that are have been prescribed for more than 30 years to prevent and treat all forms of osteoporosis (OP) and recognized as first-line drugs for its treatment are used as an example to see the...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2011-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | http://mrj.ima-press.net/index.php/mrj/article/view/391 |
id |
doaj-58b7e51f9b6f4d29a3d913ea8c72928a |
---|---|
record_format |
Article |
spelling |
doaj-58b7e51f9b6f4d29a3d913ea8c72928a2021-07-02T07:30:33ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2011-12-010479861696Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonatesI S DydykinaP S DydykinaYu V MuravyevThe paper presents a classification of adverse drug reactions and their characteristics. Bisphophonates (BP) that are have been prescribed for more than 30 years to prevent and treat all forms of osteoporosis (OP) and recognized as first-line drugs for its treatment are used as an example to see the history of investigating rare and unexpected adverse reactions. The direct correlation between the rare adverse reactions of Ps and their use remains to be proven today. The proposal to reduce the prescriptions of BPs is unfounded. The evidence for the efficacy and safety of BPs in OP has been obtained and confirmed by multiple trials and many years X real practice. Alendronate (fosavance) is the most studied BP now.http://mrj.ima-press.net/index.php/mrj/article/view/391adverse reactionsbisphosphonates |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
I S Dydykina P S Dydykina Yu V Muravyev |
spellingShingle |
I S Dydykina P S Dydykina Yu V Muravyev Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates Современная ревматология adverse reactions bisphosphonates |
author_facet |
I S Dydykina P S Dydykina Yu V Muravyev |
author_sort |
I S Dydykina |
title |
Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
title_short |
Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
title_full |
Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
title_fullStr |
Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
title_full_unstemmed |
Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
title_sort |
bases for the study of the safety of medicines. the spectrum of rare and unexpected ad-verse reactions of bisphosphonates |
publisher |
IMA-PRESS LLC |
series |
Современная ревматология |
issn |
1996-7012 2310-158X |
publishDate |
2011-12-01 |
description |
The paper presents a classification of adverse drug reactions and their characteristics. Bisphophonates (BP) that are have been prescribed for more than 30 years to prevent and treat all forms of osteoporosis (OP) and recognized as first-line drugs for its treatment are used as an example to see the history of investigating rare and unexpected adverse reactions. The direct correlation between the rare adverse reactions of Ps and their use remains to be proven today. The proposal to reduce the prescriptions of BPs is unfounded. The evidence for the efficacy and safety of BPs in OP has been obtained and confirmed by multiple trials and many years X real practice. Alendronate (fosavance) is the most studied BP now. |
topic |
adverse reactions bisphosphonates |
url |
http://mrj.ima-press.net/index.php/mrj/article/view/391 |
work_keys_str_mv |
AT isdydykina basesforthestudyofthesafetyofmedicinesthespectrumofrareandunexpectedadversereactionsofbisphosphonates AT psdydykina basesforthestudyofthesafetyofmedicinesthespectrumofrareandunexpectedadversereactionsofbisphosphonates AT yuvmuravyev basesforthestudyofthesafetyofmedicinesthespectrumofrareandunexpectedadversereactionsofbisphosphonates |
_version_ |
1721335927375134720 |